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IntrOductIOn 
More than 80% of the women face physical and psychological 
problems when they approach menopause leading to a reduction 
in the quality of life [1]. World Health Organization (WHO) described 
quality of life as an individual's insight of their situation in life in the 
base of the culture and value systems in which they habit and 
in relation to their aims, expectancies, standards and concerns. 
Studies have revealed that menopause might have an adverse 
impact on quality of life of women [2].
Several causes can disturb the quality of life in postmenopausal 
women. Stress, urinary incontinence is one of the factors that 
can influence the quality of life of women, since they evade 
social activities and limit their behavior [3]. Vulvovaginal disorders 
adversely impact sexual activity, psychosocial health and partner 
relationships [4]. More than 56% of postmenopausal women 
undergo dyspareunia affected by vaginal dryness [5], and the 
dyspareunia is correlated with reduced libido [6] and ultimately 
disturbed quality of life. The commonest urogenital symptoms 
related to menopause are vaginal dryness, followed by irritation or 
itching, discharge, and dysuria. These problems are the outcome 
of vaginal atrophy which is caused by decreased transudation 
through the vaginal epithelium and decreased cervical gland 
secretions due to post-menopausal estrogen reduction. Vaginal 
dryness is the commonest symptom of urogenital disorders in 
menopause. Vaginal atrophy is strongly associated with sexual 
disorder and lower urinary tract problems, such as frequency, 
nocturia and dysuria, also incontinence and recurring infection 
are reported more often in the existence of vaginal atrophy. 
These problems, apart from being troublesome also negatively 
influence their quality of life. Thus, before irreversible alterations 
occur, quick detection and treatment of vaginal atrophy should be 
performed [4].
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ABStrAct
Introduction: Several causes can disturb the quality of life in 
postmenopausal women. Stress, urinary incontinence is one of 
the factors that can influence the quality of life of women, since 
they evade social activities and limit their behavior. Vulvovaginal 
disorders adversely impacts sexual action, psychosocial health, 
and partner relationships. 
Aim: The aim of this study was to examine the therapeutic 
properties of vaginal cream of royal jelly and estrogen on 
quality of life, sexual and urinary problems in postmenopausal 
women.
Materials  and Methods: This  study  was  a randomized 
controlled clinical trial that was done on 90 married 
postmenopausal women 50 to 65-year-old. A total of 90 women 
were randomly distributed to three groups and were treated 
with vaginal cream of royal jelly 15%, lubricant, and conjugated 
estrogens for three months. Before and after intervention, quality 
of life and vaginal cytology were evaluated. Data was analysed 
by SPSS 16 using ANOVA and Tukey tests.
results: The results expressed that vaginal royal jelly is 
considerably more effective than conjugated estrogens and 
lubricant in the improvement of quality of life, sexual and 
urinary function in postmenopausal women (p<0.05). Results 
of Pap smear showed that improvement of vaginal atrophy 
in conjugated estrogens group was better than other groups 
(p<0.001), and there was no significant difference between 
lubricant and royal jelly groups (p=0.89). 
conclusion: The effectiveness of vaginal royal jelly in treatment 
of sexual and urinary problems of postmenopausal women is 
related to its estrogenic properties and could be suitable in 
promotion of life quality in postmenopausal women.
Postmenopausal women frequently suffer from urinary incontinence 
caused by an increase in intra-abdominal pressure such as sneezing, 
coughing, jumping, laughing and or sexual intercourse [7]. Stress 
incontinence influences sexual activity as well [8,9].
To reduce vulvovaginal atrophy (VVA) symptoms, primary 
therapies were suggested as non-hormonal vaginal lubricants, 
moisturizers and regular sexual function [10]. For women who do 
not improve by lubricants  and moisturizers, estrogen therapy was 
recommended as  a therapeutic standard [11]. Various vaginal 
estrogen compounds such as conjugated equine estrogens, 
estradiol and estriol vaginal creams, a sustained release intra-
vaginal estradiol ring and a little dose estradiol and estriol pills are 
useful therapeutic choices in the treatment of this problem [10].
AIM
The present study aimed to compare the therapeutic effects of 
vaginal cream of royal jelly and estrogen on quality of life, sexual 
and urinary function in postmenopausal women. 
MAterIAlS And MethOdS
This study was a double-blind randomized controlled clinical 
trial that was done on 90 married postmenopausal women aged 
between 50 to 65-year-old referred to Women Clinics of Hajar 
Hospital, from January 2013 to January 2014. After approving 
the research by the Ethics Committee of Shahrekord University 
of Medical Sciences, the interested women were requested to 
contribute in this clinical trial, the aims and process of the study 
were elucidated to them. All of women who signed the consent 
were included. Then, women entered their information in a 
questionnaire containing  demographic characteristics, medical 
history, pregnancy information and Contraceptive method. Finally, 
the participants were assigned and divided into three therapeutic 
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groups based on simple sampling, 27 subjects in group of 
lubricant, 22 subjects in group of conjugated estrogen, 24 subjects 
in group of royal jelly: Vaginal estrogen 0.625 mg (Conjugated 
estrogens: manufacturing Pharmaceutical Company: Aboreihan 
Bironi company, Tehran, Iran), Placebo (KY jelly manufacturing 
ABURAIHAN Pharmaceutical Company), and vaginal cream of 
royal jelly 15% in lubricant base. Total number of patients was 90 
at the beginning of the study but 73 patients were remained at 
the final. The flow diagram of participants and the allocation into 
various groups have been shown in [Table/Fig-1].
Inclusion criteria were age 50 to 65-year-old, normal Pap smear 
within the last 3 years, at least 12 months of amenorrhea and or 
having FSH test more than 40 IU, vaginal pH>5, symptoms of 
vaginal atrophy, having sexual activity, naturally menopause.
Exclusion criteria were dissatisfaction to participate in the study, 
history of sexual problems, chronic or systemic disease (e.g., 
diabetes, personal and family (first degree family) history of breast 
or endometrial cancer, prolapse grade 2 and above of bladder 
and uterus, history of endometriosis, surgery of anterior posterior 
repair (APR), personal and family (first degree family) history of 
thromboembolism, chronic liver disease, migraine, optic nerve 
disease, epilepsy and hereditary dyslipidaemia), use of hormones, 
allergy to honey, Sensitivity to estrogenic compounds and its 
products and not sexually active women viz divorced/unmarried/
widowed. 
Data were collected using the quality of life questionnaire and 
laboratory observations. The Menopause-specific Quality of Life 
(MENQOL) questionnaire is self-administered and consists of a total 
of 29 items in a 7 point Likert-scale format (ranging from “0” for “no 
symptoms” to “6” for “maximum of symptoms"). Each category 
investigate the effect of each of these menopausal problems 
during the last month: vasomotor (items 1–3), psychosocial (items 
4–10), physical (items 11–26), and sexual (items 27–29). Higher 
scores indicate better quality of life in every area and lower scores 
indicate poor quality of life. This questionnaire has been used in 
various studies in Iran and has been standardized and validated 
[12].
The questionnaire was completed pre- and post-intervention 
period by women's Resident as personal interview. In addition, 
questions related to sexual and urinary problems (5 questions) 
were considered and evaluated in this questionnaire. Cytological 
examination of the cervix and vagina was also done pre- and post-
intervention period. So that the Pap smear sampling of patients 
was done before and after the study, with the following conditions: 
Avoid having sex 24 hours before Pap smear, Lack of douching in 
the past 48 hours, Non-use of vaginal creams in the past week, 
No spotting. The sampling was performed from ectocervical and 
endocervical regions by spatula. The samples were drawn on the 
separate sections of Lam. The Lams were fixed immediately with 
96% alcohol. At the end of the day, the samples were sent to 
pathology and were interpreted by a pathologist. The percentage 
of parabasal cells observed in Pap smear was the classification 
criteria of vaginal atrophy severity. The increased parabasal cells 
and decreased superficial cells showed more severe atrophy [13]. 
Collaborator pathologist who was unaware of the study groups, 
classified severity of atrophy based on the percentage of parabasal 
cells in the smears of patients: Score 1; the lack of parabasal cells 
(no atrophy), Score 2; 1-20% parabasal cells (mild atrophy), Score 
3; 20-50% parabasal cells (moderate atrophy), Score 4; >50% 
parabasal cells (sever atrophy).
[table/Fig-1]: Flow diagram of participating of three groups during study.
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The creams were prepared in the same tube. Patients, physicians 
and pathologists were unaware of the type of medication prescribed. 
At the beginning of the study, Patients were instructed how to use 
the vaginal creams: First and second week; one applicator per 
night, third and fourth week; an applicator as four nights a week, 
the fifth week until the end of the twelfth week; an applicator as 
two nights a week. The intervention period was three months.
The antioxidant activity of Royal jelly was evaluated by DPPH (2, 
2-diphenyl-1-picrylhydrazyl) assay [8].
StAtIStIcAl AnAlySIS
Data were analysed by SPSS 16 software. Descriptive statistics 
were obtained for all variables. The normality of variables was 
tested by the Kolmogorov-Smirnov test and results were reported 
using frequency, mean, standard deviation. Also, data analysis 
was performed using ANOVA and Tukey tests.
reSultS 
In this study, 90 postmenopausal women were divided into three 
groups consisting of 27 subjects in group of lubricant, 22 subjects 
in group of conjugated estrogen, 24 subjects in group of royal 
jelly.
The mean age of participants was 53.57±4.89-year-old, and 
the mean age of onset of menopause in women was estimated 
48.33±4.97-year-old in the age range 45 to 57. The mean BMI of 
samples was 28.5±4.17 in the range of 19 to 41%.
Most of the participants (54.4%) were illiterate. Average number of 
delivery was 5.21±2.66, and 95.8% of women were housekeepers. 
The mean age of participants, age at menopause, education, body 
mass index, career status and mean number of delivery in the 
three groups were not significantly different [Table/Fig-2].
In addition, at the beginning of the study, the severity of vaginal 
atrophy and the mean quality of life of women in the three groups 
were similar and, therefore, the groups were matched [Table/
Fig-3].
ANOVA test showed significant differences of all aspects of life 
quality and vaginal cytology (vaginal atrophy) between three groups 
at the end of intervention (p<.001). Tukey test showed that vaginal 
royal jelly and conjugated estrogen are more effective than vaginal 
lubricant in improving the quality of life and sexual and urinary 
problems in postmenopausal women (p<.05). Effectiveness of royal 
jelly in improving the quality of life was more than Premarin, but the 
difference between two groups was not significant (p>.05).
The results of Pap smear showed that the group of conjugated 
estrogens had the most reduction in the parabasal cells of the vagina 
and improvement of vaginal atrophy. Tukey test showed that there 
were significant differences between the groups receiving lubricant 
and conjugated estrogens and the group receiving conjugated 
estrogen had lower parabasal cells (p=0.004). However, there was 
no significant difference between royal jelly group and lubricant 
group, (p=0.89). Also, significant differences was observed 
between the groups receiving royal jelly and Conjugated estrogens 
(p=.02), and status of vaginal atrophy in patients taking conjugated 
estrogens was better than royal jelly group [Table/Fig-4].
The amounts of phenols, flavonoid and flavonols of Royal jelly 
measured 12.2 mg/g, 45.62 mg/g and 60.47 mg/g, respectively. 
Antioxidant activity of Royal jelly by DPPH method was determined 
15%. 
lubricant 
group
premarin 
group
Royal jelly 
group
p-value 
Vasomotor problems 8.88±5.45 8.45±5.08 10.37±5.60 0.44
Psychosocial problems 14.03±8.64 17.54±8.79 18.54±9.90 0.18
Physical Problems 41.77±18.54 41.31±14.84 50.41±17.52 0.12
Sexual Problems 11.37±5.85 12.00±5.30 12.91±5.83 0.62
Quality of life 76.07±29.20 79.31±26.24 92.25±30.56 0.12
Vaginal atrophy 2.26±1.25 2.27±1.31 2.12±1.19 0.89
[table/Fig-3]: Comparison of quality of life and severity of vaginal atrophy in the three 
groups, at the beginning of the studya 
a Data are presented as Mean ± SD.
lubricant 
group
Royal jelly 
group
premarin 
group
p-value 
Quality of life -.3.18±9.37 -30.36±14.39 -35.29±20.29 <.001
Sexual Function -.81±3.06 -4.45±2.93 -4.83±4.17 <.001
Urinary problems -.59±2.04 -2.50±2.57 -3.95±3.68 <.001
Vaginal atrophy -.38±.63 -1.23±1.26 -.51±.67 0.004
[table/Fig-4]: Comparison of changes in quality of life and vaginal atrophy in 
groupsa 
a Data are presented as Mean ± SD.
dIScuSSIOn
Finding of the study showed that vaginal cream of royal jelly is 
significantly more effective than vaginal cream of conjugated 
estrogens and lubricant in improvement of quality of life and sexual 
and urinary problems in postmenopausal women. In addition, the 
conjugated estrogens was more effective than the lubricant in 
improving various aspects of quality of life, and the rate of vaginal 
atrophy in the group receiving conjugated estrogens compared to 
the other two groups significantly reduced.
In Bachmann et al., study, the estrogenic properties of RJ 
were examined using various approaches. This study reported 
evidence that RJ has estrogenic activities via interaction with 
estrogen receptors after endogenous gene expressions [13] that 
is consistent with our results.
Nakaya et al., found that royal jelly have an anti-environmental 
estrogen property. Royal jelly inhibits the stimulatory effect 
of growth of Bisphenol A on MCF-7 cells. Bisphenol A is an 
environmental estrogen that increases proliferation of MCF-7 cells 
of human breast cancer [14].
Antioxidant activities of RJ were investigated in several studies: 
it was shown that the antioxidative activities and ROS activities 
against active oxygen species of RJ were high in the sample 
with a low protein concentration. It was indicated that royal jelly 
possesses much higher antioxidative activity and ROS activity [15]. 
In a study by Cavusoglu, Royal jelly was shown to have antioxidant 
activity against cadmium-induced non toxicity and oxidative stress 
in albino mice [16].
Koc et al., found that RJ supplementation enhanced considerably 
glutathione peroxidase activities and erythrocyte superoxide 
dismutase and considerably decreased Malondialdehyde 
levels [17].
lubricant 
group
premarin 
group
Royal jelly 
group
p-value 
Age, year 54.37±4.75 53.72±5.12 52.79±4.88 0.52
Menopause age, y 49.16±3.81 49.44±2.52 46.42±6.98 0.09
Body mass index, kg/m2 29.43±3.95 26.97±4.16 28.98±4.17 0.10
Number of delivery 5.92±2.49 5.04±2.47 4.66±2.92 0.23
Employment 
status
Housekeeper 26 20 21 0.14
Employee 0 1 3
Education Illiterate 13 11 13 0.34
Elementary 8 4 3
Secondary 
school
3 2 1
High School 
and Diploma 
1 1 4
College 0 1 3
[table/Fig-2]: Demographic Characteristics of the Participantsin three groupsa 
a Data are presented as Mean ± SD.
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In a study by Sinha and her colleague, it was shown that Local 
estrogen also is highly effective in relieving symptoms of urogenital 
atrophy and enhanced libido, and in improving sexual function in 
symptomatic postmenopausal women [20] that is in accordance 
with our findings.
In a meta-analysis study by Cardozo et al., ten randomized clinical 
trials were evaluated and it was indicated that estrogen therapy 
was an efficient treatment against vaginal disorders, and there was 
greater improvement in vaginal problems and cytological results 
with vaginal estrogen therapy compared to oral estrogen [21] that 
is consistent with our study.
Similar to our findings, the results of Long et al., study suggested 
that estrogen therapy alone enhances the vaginal blood stream 
and improves some sexual activities in postmenopausal women. 
Compared with systemic therapy, topical vaginal compounds were 
shown to associate with enhanced symptom relief [22]. Raymundo 
et al., showed that vaginal treatment with vaginal cream of 
conjugated equine estrogens resulted favourable changes in the 
vaginal tissues [23].
Besides, Al-Baghdadi et al., showed that topical vaginal 
estrogen compounds reverse atrophic alterations and relieve the 
symptoms, and prevent systemic effects [24]. In a study by Sinha 
et al., it was suggested that Lubricants are frequently used during 
intercourse to provide temporary alleviation from vaginal dryness 
and dyspareunia [25].
In addition, Nachtigall showed that moisturizers recover vaginal 
dryness, itching, dyspareunia, but their impacts are lesser than 
estrogen therapy [26] that is again consistent with our findings. 
Supporting our result, Raghunandan et al., study investigated 
the effects of local estrogen with or without local testosterone on 
sexual and urogenital health in postmenopausal women. They 
found that local estrogen either alone or with androgen is effective 
in recovery of urogenital atrophy symptoms and sexual activity in 
postmenopausal women without any side effects [27].
Ko et al., found that Stress urinary incontinence is frequently 
associated with adverse effects on quality of life of patients. 
Severity of incontinence, one's response to problems and physical 
image of oneself are among the factors affecting the quality of 
life [28]. The study by Perrotta suggested that topical estrogen 
therapy decreases the symptoms and prevent urinary tract 
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Investigating natural products affecting quality of life and health of 
postmenopausal women is essential [30]. Royal jelly is one of the 
natural products that has several useful properties. RJ has been 
demonstrated to possess abundant functional properties such as 
anti-inflammatory activity, antibacterial activity, vasodilative and 
hypotensive activities, antioxidant activity, disinfectant action, 
antitumour activity and antihyper cholesterolemic activity [18]. 
cOncluSIOn 
In this study, vaginal royal jelly was effective in improving 
symptoms of sexual and urinary problems and quality of life in 
postmenopausal women. Given to the various properties of royal 
jelly and its effectiveness on quality of life in postmenopausal 
women, further studies are recommended for use of royal jelly in 
improving menopausal symptoms.
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